3William J,Gradishar,Sergei Tjulandin,et al.Phase Ⅲ trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer[J].J Clin Oncol,2005,23(31):7794-7803.
4Ellis M,Hayes DF,Lippman ME.Treatment of metastatic breast cancer[A].Harris JR,Lippman ME,Morrow M,et al.Diseases of the breast[M].Philadelphia:Lippincott Williams & Wilkins,2004.
5Colozza M,de Azambuja E,Personeni N,et al.Achievements in systemic therapies in the pregenomic era in metastatic breast cancer[J].Oncologist,2007,12:253-270.
6O' Brien ME,Wigler N,Inbar M,et al.Reduced cardiotoxicity and comparable efficacy in a phase Ⅲ trial of pegylated liposomal doxorubicin HCl(CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer[J].Ann Oncol,2004,15:440-449.
7Biganzoli L,Coleman R,Minisini A,et al.A joined analysis of two European Organization for the Research and Treatment of Cancer(EORTC) studies to evaluate the role of pegylated liposomal doxorubicin(Caelyx) in the treatment of elderly patients with metastatic breast cancer[J].Crit Rev Oncol Hematol,2007,61:84-89.
8Batist G,Harris L,Azarnia N,et al.Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin:Results of a retrospective analysis[J].Anticancer Drugs,2006,17:587-595.
9Bria E,Giannarelli D,Felici A,et al.Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma[J].J Clin Oncol,2005,103:672-679.
10Sledge GW,Neuberg D,Bernardo P,et al.Phase Ⅲ trial of doxorubicin,paclitaxel,and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer:An intergroup trial(E1193)[J].J Clin Oncol,2003,21:588-592.
5Vahdat LT, Tomas E,Li R,et al. Phase Ⅲ trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with mestastatic breast cancer(MBC) previously treated or resistant to an anthracycline and resistant to taxanes [ J ]. Proc Am Soc Clin Oncol,2007,25 (18s) :33s.
6Kamby C, Nielsen D. Routine management of disseminated disease with special emphasis on bone-directed therapies [ M ]//Bonadonna G, Hortobagyi G, Gianni AM, eds. Textbook of Breast Cancer. 2nd ed. London: Martin Dunitz,2001:161 - 181.
7徐兵河 孙燕.乳腺癌内科治疗的策略及研究.乳腺病杂志,2003,1(1):1-3.
8O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase Ⅲ trial of pegylated liposomal doxorubicin HCl ( CAELYX/Doxil ) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. [ J ]. Ann Oncd,2004,15 (3) : 440 -449.
9Chan S,Davidson N,Juozaityte E,et al. Phase Ⅲ trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer [ J ]. Ann Oncd,2004,15 : 1527 - 1534.
10Gregory RK, Powles TJ, Chang JC, et al. A randomized trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast [ J ]. Eur J Cancer, 1997,33:2194 - 2197.
